Shahbazi Foroud, Shojaei Lida
Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Department of Clinical Pharmacy, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Curr Drug Saf. 2025;20(2):241-246. doi: 10.2174/0115748863299100240507052341.
Serotonin syndrome is a potentially life-threatening condition that can occur as a result of the therapeutic use of serotonergic medications or drug interaction. In this study, we describe two cases of serotonin syndrome-associated hypertensive crisis following linezolid use.
The first patient was a 52-year-old female who was admitted due to a diabetic foot infection and pneumonia associated with a decreased consciousness level. Serotonin syndrome occurred 24 hours after starting the linezolid use. Resistant hypertension was the main hemodynamic finding. It could not be controlled with amlodipine, valsartan, prazosin, and nitroglycerin infusion. Resistant hypertension and other symptoms of serotonin syndrome were resolved about 48 hours after discontinuation of linezolid use. The second case was a man with a history of kidney transplant, diabetes, and hypertension. He was admitted to the ICU due to severe COVID-19. Broad-spectrum antibiotics [linezolid, cefepime], and remdesivir was initiated. Following intubation, continuous infusion of fentanyl was used for sedation. Within 24 hours after fentanyl and linezolid initiation, severe agitation, eye clonus, hyperreflexia, hypertension [160-186 /90-110 mmHg], and tachycardia [>100/min] were noted. With the possible diagnosis of serotonin syndrome, fentanyl was discontinued, and morphine was initiated. The patient's symptoms improved 48 hours after discontinuation of fentanyl.
Both patients had a history of well- controlled hypertension. Hypertensive crisis has occurred after recent or concurrent use of serotonergic agents with linezolid. A thorough evaluation of the patient's medical history and current condition can help clinicians prevent this syndrome in critically ill patients.
血清素综合征是一种潜在的危及生命的病症,可能因使用血清素能药物或药物相互作用而发生。在本研究中,我们描述了两例使用利奈唑胺后出现血清素综合征相关高血压危象的病例。
首例患者为一名52岁女性,因糖尿病足感染和意识水平下降相关的肺炎入院。在开始使用利奈唑胺24小时后发生血清素综合征。顽固性高血压是主要的血流动力学表现。使用氨氯地平、缬沙坦、哌唑嗪和静脉输注硝酸甘油均无法控制。停用利奈唑胺约48小时后,顽固性高血压和血清素综合征的其他症状得到缓解。第二例患者是一名有肾移植、糖尿病和高血压病史的男性。他因重症新型冠状病毒肺炎入住重症监护病房。开始使用广谱抗生素[利奈唑胺、头孢吡肟]和瑞德西韦。插管后,持续输注芬太尼用于镇静。在开始使用芬太尼和利奈唑胺后24小时内,出现严重躁动、眼球阵挛、反射亢进、高血压[160 - 186 /90 - 110 mmHg]和心动过速[>100次/分钟]。在可能诊断为血清素综合征后,停用芬太尼,并开始使用吗啡。停用芬太尼48小时后患者症状改善。
两名患者既往均有血压控制良好的病史。近期或同时使用血清素能药物与利奈唑胺后发生了高血压危象。对患者病史和当前状况进行全面评估有助于临床医生在重症患者中预防这种综合征。